- Home
- IBG vs CMND Comparison
IBG vs CMND Comparison
Compare IBG & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- CMND
- Stock Information
- Founded
- IBG 2018
- CMND 2017
- Country
- IBG Australia
- CMND Canada
- Employees
- IBG N/A
- CMND N/A
- Industry
- IBG Beverages (Production/Distribution)
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- IBG Consumer Staples
- CMND Health Care
- Exchange
- IBG Nasdaq
- CMND Nasdaq
- Market Cap
- IBG 5.4M
- CMND 5.3M
- IPO Year
- IBG 2024
- CMND N/A
- Fundamental
- Price
- IBG $0.73
- CMND $0.99
- Analyst Decision
- IBG Strong Buy
- CMND
- Analyst Count
- IBG 1
- CMND 0
- Target Price
- IBG N/A
- CMND N/A
- AVG Volume (30 Days)
- IBG 6.2M
- CMND 311.2K
- Earning Date
- IBG 08-19-2025
- CMND 09-15-2025
- Dividend Yield
- IBG N/A
- CMND N/A
- EPS Growth
- IBG N/A
- CMND N/A
- EPS
- IBG N/A
- CMND N/A
- Revenue
- IBG $2,931,243.00
- CMND N/A
- Revenue This Year
- IBG N/A
- CMND N/A
- Revenue Next Year
- IBG N/A
- CMND N/A
- P/E Ratio
- IBG N/A
- CMND N/A
- Revenue Growth
- IBG N/A
- CMND N/A
- 52 Week Low
- IBG $0.44
- CMND $0.80
- 52 Week High
- IBG $3.35
- CMND $2.18
- Technical
- Relative Strength Index (RSI)
- IBG N/A
- CMND 49.14
- Support Level
- IBG N/A
- CMND $0.95
- Resistance Level
- IBG N/A
- CMND $1.03
- Average True Range (ATR)
- IBG 0.00
- CMND 0.06
- MACD
- IBG 0.00
- CMND -0.01
- Stochastic Oscillator
- IBG 0.00
- CMND 14.23
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.